Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective study evaluating switching and discontinuation rates of apixaban, rivaroxaban or dabigatran therapy in patients with nonvalvular atrial fibrillationin the US

Trial Profile

A retrospective study evaluating switching and discontinuation rates of apixaban, rivaroxaban or dabigatran therapy in patients with nonvalvular atrial fibrillationin the US

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 22 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
  • Indications Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 22 May 2019 Results evaluating the association of switching to another oral anticoagulant vs. continuing with apixaban treatment among elderly patients with nonvalvular atrial fibrillation presented at the 24th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 13 Dec 2018 New trial record
    • 14 Nov 2018 Results presented at the 91st Annual Scientific Sessions of the American Heart Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top